ENDOPHILIN A3 IMMUNOHISTOCHEMICAL HETEROGENEITY IN PANCREATIC DUCTAL ADENOCARCINOMA

Authors

  • Andreea RUSU “Grigore T. Popa” University of Medicine and Pharmacy Iasi
  • Ludmila LOZNEANU “Grigore T. Popa” University of Medicine and Pharmacy Iasi
  • Simona-Eliza GIUSCA “Grigore T. Popa” University of Medicine and Pharmacy Iasi
  • Irina-Draga CARUNTU “Grigore T. Popa” University of Medicine and Pharmacy Iasi

Abstract

Background and aim: Pancreatic ductal adenocarcinoma (PDAC) represents a malignant proliferation with minimally improved survival in last decades that presents systematic changes in classification framework based on new molecular and morphological data. Endophilin A3 (EndoA3), a protein involved in non-conventional endocytosis that was recently integrated in modulation of tumor cell adhesion molecule CD166/ALCAM, has not been evaluated in PDAC. Materials and methods: EndoA3 immunoreaction were qualitatively and semi-quantitatively analyzed in 87 cases of PDAC. Statically association between classic PDAC prognostic factors and Endophilin A3 immunohistochemical profile were evaluated. Results: Data analysis revealed that EndoA3 immunoprofile is associated with tumor degree of differentiation (p = 0.01). For the others microscopic prognostic factors there were no significant statistical correlations. Although not statistically significant, patients with high EndoA3 score presented the lowest survival. Conclusions: Endophilin A3 expressed in PDAC presents a cytoplasmic, diffuse or granular, tumor staining, but also a stromal staining. High EndoA3 immunoexpression appears to be associated with a negative prognosis in PDAC.

Author Biographies

  • Andreea RUSU, “Grigore T. Popa” University of Medicine and Pharmacy Iasi

    Faculty of Medicine
    Department of Morpho-Functional Sciences (I)

  • Ludmila LOZNEANU, “Grigore T. Popa” University of Medicine and Pharmacy Iasi

    Faculty of Medicine
    Department of Morpho-Functional Sciences (I)

  • Simona-Eliza GIUSCA, “Grigore T. Popa” University of Medicine and Pharmacy Iasi

    Faculty of Medicine
    Department of Morpho-Functional Sciences (I)

  • Irina-Draga CARUNTU, “Grigore T. Popa” University of Medicine and Pharmacy Iasi

    Faculty of Medicine
    Department of Morpho-Functional Sciences (I)

References

1. Gill AJ, Klimstra DS, Lam AK, Washington MK. Tumors of the pancreas. In: D Lokuhetty, V White V, R Watanabe, I Cree editors. WHO Classification of Tumors of the Digestive System. Lyon, Frace: IARC Press, 2019, 295-332.
2. Dell'Aquila E, Fulgenzi CAM, Minelli A, et al. Prognostic and predictive factors in pancreatic cancer. Oncotarget 2020; 11: 924-941.
3. Kjaerulff O, Brodin L, Jung A. The structure and function of endophilin proteins. Cell Biochem Biophys 2011; 60: 137-154.
4. Poudel KR, Roh-Johnson M, Su A, et al. Competition between TIAM1 and membranes balances endophilin A3 activity in cancer metastasis. Dev Cell 2018; 45: 738-752.e6.
5. Lin Z, Liu Z, Tan X, Li C. SH3GL3 functions as a potent tumor suppressor in lung cancer in a SH3 domain dependent manner. Biochem Biophys Res Commun 2021; 534: 787-794.
6. Khan I, Steeg PS. Endocytosis: a pivotal pathway for regulating metastasis. Br J Cancer 2021; 124: 66-75.
7. Shafaq-Zadah M, Dransart E, Johannes L. Clathrin-independent endocytosis, retrograde trafficking, and cell polarity. Curr Opin Cell Biol 2020; 65: 112-121.
8. Renard HF, Tyckaert, F, Lo Giudice C, et al. Endophilin-A3 and galectin-8 control the clathrin-independent endocytosis of CD166. Nat Commun 2020; 11: 1457.
9. Sun H, Bhandari K, Burrola S, Wu J, Ding WQ. Pancreatic ductal cell-derived extracellular vesicles are effective drug carriers to enhance paclitaxel’s efficacy in pancreatic cancer cells through clathrin-mediated endocytosis. Int J Mol Sci 2022; 23: 4773.
10. JD Brierley, MK Gospodarowicz, C Wittekind, editors. TNM Classification of malignant tumours, Oxford, New Jersey: John Wiley & Sons, Inc. 2017, 102-105.
11. Schlitter AM, Segler A, Steiger K et al. Molecular, morphological and survival analysis of 177 resected pancreatic ductal adenocarcinomas (PDACs): identification of prognostic subtypes. Sci Rep 2017; 7: 41064.
12. Kalimuthu SN, Wilson GW, Grant RC, et al. Morphological classification of pancreatic ductal adeno-carcinoma that predicts molecular subtypes and correlates with clinical outcome. Gut 2020, 69: 317-328
13. Coppola D, Khalil F, Eschrich SA, Boulware D, Yeatman T, Wang HG. Down-regulation of Bax-interacting factor-1 in colorectal adenocarcinoma. Cancer 2008; 113: 2665-2670.
14. Renard HF, Boucrot E. Unconventional endocytic mechanisms. Curr Opin Cell Biol 2021; 71: 120-129.
15. Delic S, Lottmann N, Jetschke K, Reifenberger G, Riemenschneider MJ. Identification and functional validation of CDH11, PCSK6 and SH3GL3 as novel glioma invasion-associated candidate genes. Neuropathol Appl Neurobiol 2012; 38: 201-212.
16. Aramaki Y, Ogawa K, Toh Yet al. Direct interaction between metastasis-associated protein 1 and endophilin 3. FEBS Lett 2005; 579: 3731-3736.
17. Tachezy M, Zander H, Marx AH, et al. ALCAM (CD166) expression and serum levels in pancreatic cancer. PLoS One 2012; 7: e39018.
18. Fujiwara, K, Ohuchida K, Sada M, et al. CD166/ALCAM expression is characteristic of tumorigenicity and invasive and migratory activities of pancreatic cancer cells. PLoS One 2014, 9: e107247.
19. Yang Y, Sanders AJ, Ruge F, et al. Activated leukocyte cell adhesion molecule (ALCAM)/CD166 in pancreatic cancer, a pivotal link to clinical outcome and vascular embolism. Am J Cancer Res 2021; 11: 5917-5932.

Additional Files

Published

2023-12-21